Personalized support after first psychosis: a 3-Year test
NCT ID NCT05116514
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether regular, personalized follow-up by a trained case manager can reduce the chance of another psychotic episode over three years in people aged 16 to 30 who have just had their first episode. 256 participants will be randomly assigned to either standard care or case management. The goal is to see if this approach can be rolled out widely to improve recovery and prevent relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- case management (regular personalized follow-up by a trained case manager)
- What this could lead to
- If it works, this could provide a scalable way to improve long-term outcomes for young people after a first psychotic episode, reducing relapse and hospitalizations.
- What could go wrong
- This is an open-label study, so both patients and staff know who gets the intervention, which can bias results. It is also relatively small (256 people) and focuses on a specific age group, so findings may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSYCHOTIC EPISODE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CH Saint Marie Clermont-Ferrand
NOT_YET_RECRUITINGClermont-Ferrand, France
-
CHU Nice
NOT_YET_RECRUITINGNice, France
-
CHU de Montpellier
RECRUITINGMontpellier, France
-
CHU de Nîmes
RECRUITINGNîmes, France
-
CHU de TOULOUSE
NOT_YET_RECRUITINGToulouse, Choisir Une Région, 31, France
-
Centre Hospitalier Léon-Jean Grégory
RECRUITINGThuir, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.